论文部分内容阅读
目的探讨山莨菪碱与替罗非班联合辅助治疗急性心肌梗死(AMI)的效果及安全性。方法对照组经冠状动脉内给予替罗非班,观察组在此基础上联合山莨菪碱,观察对比两组临床疗效及安全性。结果治疗后10 min,观察组TIMI分级及TIMI血流帧数均优于对照组(P<0.05);术后1个月,观察组左室射血分数(LVEF)、左室舒张末期容积(LVEDV)改善程度均优于对照组(P<0.05);术后1个月,观察组不良心血管事件(MACE)发生率为9.5%,明显低于对照组的33.3%,两组比较差异有统计学意义(P<0.05)。结论替罗非班与山莨菪碱联合辅助治疗AMI可进一步逆转无复流现象,并可改善心功能,对预防不良心血管事件有重要价值。
Objective To investigate the efficacy and safety of combination of anisodamine and tirofiban in the treatment of acute myocardial infarction (AMI). Methods The control group was given tirofiban through coronary artery. On the basis of this, the observation group was given anisodamine, and the clinical efficacy and safety of the two groups were observed and compared. Results At 10 min after treatment, the TIMI grade and the number of TIMI flow frames in the observation group were better than those in the control group (P <0.05). At 1 month after operation, the left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (P <0.05). The incidence of adverse cardiovascular events (MACE) in the observation group was 9.5% at 1 month after operation, which was significantly lower than that in the control group (33.3%). There was significant difference between the two groups Statistical significance (P <0.05). Conclusion The combination of tirofiban and anisodamine in the treatment of AMI can further reverse the no-reflow phenomenon and improve cardiac function, which is of great value in the prevention of adverse cardiovascular events.